CytoDyn Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients

VANCOUVER, Washington, April 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the“Company " ), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news